Press Releases.

Completed Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease ("ADPKD")

Definitive Agreement for $19.4 Million in Gross Proceeds

First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease ("ADPKD")

Regulus to Receive Remaining $5 Million Payment for Enrollment Milestone

Proceeds Used to Repay Debt Principal with Oxford Finance

Completion of Dosing in Phase 1 Multiple Ascending Dose Study ("MAD") of RGLS4326 in Healthy Volunteers for Autosomal Dominant Polycystic Kidney Disease ("ADPKD")

Initiated Third and Final Cohort of the Multiple Ascending Dose Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

FDA Removal of Partial Clinical Hold for Phase I Multiple Ascending Dose Study of RGLS4326

Regulus Plans to Re-Initiate Clinical Studies in Q1 2020

Receipt of Final Reports from the Chronic Toxicity Studies for Submission of Complete Response to Reinitiate the Multiple Ascending Dose Clinical Study for RGLS4326

Closing of First Tranche of $41.8 Million Private Placement of Equity

Data Requirements Defined To Reinitiate Multiple Ascending Dose And Chronic Dose Studies With RGLS4326

Closing of First Tranche of $41.8 Million Private Placement of Equity

Term Loan Amended to Provide Up to Two Years of Interest Only Payments and Extension of Maturity Date to May 2022

Up to $41.8 Million in Gross Proceeds to be Funded in Two Tranches

Favorable Pharmacological Properties Exhibited in Preclinical Models of NASH

No Adverse or Other Significant Findings to Date Across All Dose Groups Tested

Single Dose of Lead anti-miR-10b Compound in Combination with temozolomide Resulted in over 150% Increase in Median Survival

$47 Million Restructured Sanofi Collaboration Executed

Sanofi Will Assume Development of RG-012 for Alport syndrome